- Home
- NXDT vs OBIO Comparison
NXDT vs OBIO Comparison
Compare NXDT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- OBIO
- Stock Information
- Founded
- NXDT 2012
- OBIO 2017
- Country
- NXDT United States
- OBIO United States
- Employees
- NXDT N/A
- OBIO N/A
- Industry
- NXDT Investment Managers
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- NXDT Finance
- OBIO Health Care
- Exchange
- NXDT Nasdaq
- OBIO Nasdaq
- Market Cap
- NXDT 227.2M
- OBIO 198.2M
- IPO Year
- NXDT N/A
- OBIO N/A
- Fundamental
- Price
- NXDT $4.95
- OBIO $4.72
- Analyst Decision
- NXDT
- OBIO Strong Buy
- Analyst Count
- NXDT 0
- OBIO 4
- Target Price
- NXDT N/A
- OBIO $16.25
- AVG Volume (30 Days)
- NXDT 133.6K
- OBIO 50.3K
- Earning Date
- NXDT 01-01-0001
- OBIO 03-26-2025
- Dividend Yield
- NXDT 9.66%
- OBIO N/A
- EPS Growth
- NXDT N/A
- OBIO N/A
- EPS
- NXDT 0.99
- OBIO N/A
- Revenue
- NXDT N/A
- OBIO $2,647,000.00
- Revenue This Year
- NXDT N/A
- OBIO $22.61
- Revenue Next Year
- NXDT N/A
- OBIO $16.64
- P/E Ratio
- NXDT $6.41
- OBIO N/A
- Revenue Growth
- NXDT N/A
- OBIO N/A
- 52 Week Low
- NXDT $5.89
- OBIO $3.96
- 52 Week High
- NXDT $13.07
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- NXDT 30.53
- OBIO 38.59
- Support Level
- NXDT $4.92
- OBIO $5.20
- Resistance Level
- NXDT $5.12
- OBIO $5.98
- Average True Range (ATR)
- NXDT 0.15
- OBIO 0.42
- MACD
- NXDT -0.02
- OBIO -0.07
- Stochastic Oscillator
- NXDT 3.80
- OBIO 2.70
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. Revenue sources include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates primarily through its operating partnership and wholly owned subsidiaries.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.